Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease after Ileocolonic Resection

Miguel Regueiro, B. G. Feagan, Bin Zou, Jewel Johanns, Marion A. Blank, Marc Chevrier, Scott Plevy, John Popp, Freddy J. Cornillie, M. Lukas, Silvio Danese, Paolo Gionchetti, Stephen B. Hanauer, Walter Reinisch, W. J. Sandborn, Dario Sorrentino, Paul Rutgeerts, H. Debinski, T. Florin, D. HetzelI. Lawrance, G. Radford-Smith, A. Sloss, D. Sorrentino, S. Gassner, T. Haas, G. Reicht, W. Reinisch, M. Strasser, H. Vogelsang, P. Bossuyt, O. Dewit, G. D'Haens, D. Franchimont, E. Louis, S. Vermeire, C. N. Bernstein, R. Bourdages, N. Chiba, S. S. Dhalla, B. G. Feagan, R. N. Fedorak, J. R. Lachance, R. Panaccione, M. Ropeleski, B. Singh Salh, M. Lukas, J. F. Colombel, M. Allez, P. Desreumaux, J. L. Dupas, J. C. Grimaud, X. Hebuterne, D. Laharie, E. Lerebours, L. Peyrin-Biroulet, J. M. Reimund, S. Viennot, F. Zerbib, C. Antoni, R. Atreya, D. C. Baumgart, C. Berg, U. Boecker, G. Bramkamp, C. Bünning, R. Ehehalt, S. Howaldt, T. Kucharzik, H. G. Lamprecht, J. Mudter, J. C. Preiss, S. Schreiber, U. Seidler, I. Altorjay, J. Banai, P. L. Lakatos, M. Varga, A. Vincze, I. Avni-Biron, S. Fishman, G. M. Fraser, E. Goldin, D. Rachmilewitz, V. Annese, S. Ardizzone, L. Biancone, F. Bossa, S. Danese, W. Fries, P. Gionchetti, G. Maconi, G. Terrosu, P. Usai, G. R. D'Haens, R. B. Gearry, J. Hill, D. S. Rowbotham, M. Schultz, R. S. Stubbs, D. Wallace, R. S. Walmsley, J. Wyeth, E. Malecka-Panas, L. Paradowski, J. Regula, I. P. Beales, S. Campbell, A. B. Hawthorne, M. Parkes, S. P. Travis, J. P. Achkar, B. W. Behm, S. J. Bickston, K. J. Brown, M. V. Chiorean, W. J.S. Devilliers, D. E. Elliott, D. Grunkmeier, J. W. Hamilton, S. B. Hanauer, J. S. Hanson, R. Hardi, D. J. Helper, H. Herfarth, P. D.R. Higgins, W. H. Holderman, R. Kottoor, M. D. Kreines, B. I. Leman, X. Li, E. V. Loftus, M. Noar, I. Oikonomou, J. Onken, K. A. Peterson, R. P. Phillips, C. W. Randall, M. Ricci, T. Ritter, D. T. Rubin, M. Safdi, W. J. Sandborn, L. Sauberman, E. Scherl, R. P. Schwarz, S. Sedghi, I. Shafran, C. A. Sninsky, I. Stein, J. Swoger, J. Vecchio, D. I. Weinberg, L. D. Wruble, V. Yajnik, Z. Younes

Research output: Contribution to journalArticlepeer-review

159 Citations (Scopus)


Background & Aims Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We performed a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence. Methods We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD in 297 patients at 104 sites worldwide from November 2010 through May 2012. All study patients had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 weeks. The primary end point was clinical recurrence, defined as a composite outcome consisting of a CD Activity Index score >200 and a ≥70-point increase from baseline, and endoscopic recurrence (Rutgeerts score ≥i2, determined by a central reader) or development of a new or re-draining fistula or abscess, before or at week 76. Endoscopic recurrence was a major secondary end point. Results A smaller proportion of patients in the infliximab group had a clinical recurrence before or at week 76 compared with the placebo group, but this difference was not statistically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: -1.3% to 15.5%; P =.097). A significantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.2%; P

Original languageEnglish
Pages (from-to)1568-1578
Number of pages11
Issue number7
Publication statusPublished - 1 Jun 2016


Dive into the research topics of 'Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease after Ileocolonic Resection'. Together they form a unique fingerprint.

Cite this